TC
EPRS

TFS Capital’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

TFS Capital’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-80,294
Closed -$355K – 1123
2015
Q3 		$355K Buy
80,294
+65,722
+451% +$386K 0.03% 624
2015
Q2 		$83K Buy
14,572
+1,112
+8% +$7.59K 0.01% 824
2015
Q1 		$120K Buy
+13,460
New +$108K 0.01% 858

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TFS Capital's EPRS Position: Q4 2015 in Review

TFS Capital sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q4 2015, closing a stake of 80,294 shares — an estimated $355K sold.

TFS Capital first reported a position in EPRS in Q1 2015 and held it in 3 quarters. The position peaked at $355K in Q3 2015. 45 funds tracked by Wall St. Rank hold EPRS as of Q4 2015.

  • TFS Capital reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q4 2015 after selling out during the quarter.
  • TFS Capital sold 80,294 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q4 2015, an estimated $355K.
  • TFS Capital first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q1 2015 and held it in 3 quarters.
  • TFS Capital's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $355K in Q3 2015.
  • 45 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q4 2015.

Based on TFS Capital's 13F filing for Q4 2015, filed 29 Jan 2016.